R
23.35
-0.86 (-3.55%)
| Previous Close | 24.21 |
| Open | 24.21 |
| Volume | 69,542 |
| Avg. Volume (3M) | 455,326 |
| Market Cap | 11,546,315,776 |
| Price / Book | 2.58 |
| 52 Weeks Range | |
| Earnings Date | 2 Jun 2026 |
| Diluted EPS (TTM) | -0.010 |
| Total Debt/Equity (MRQ) | 1.04% |
| Current Ratio (MRQ) | 41.92 |
| Operating Cash Flow (TTM) | -4.00 M |
| Levered Free Cash Flow (TTM) | -1.88 M |
| Return on Assets (TTM) | -28.11% |
| Return on Equity (TTM) | -43.18% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Regencell Bioscience Holdings L | - | - |
AIStockmoo Score
-0.3
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.25 |
|
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune systems. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 93.84% |
| % Held by Institutions | 0.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Seven Fleet Capital Management Lp | 31 Dec 2025 | 4,400 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |